Last updated: November 8, 2025
Introduction
China Patent CN110152005, titled "Method for Treating Tumor with Targeted Therapy," was granted on January 20, 2021, and assigned to Shanghai Pharmaceuticals Holding Co., Ltd. This patent claims a novel therapeutic approach involving targeted agents for tumor treatment, with implications for oncology drug development and personalized medicine. This analysis scrutinizes the patent’s scope, claims, and the surrounding patent landscape to facilitate strategic patent positioning and assess potential competitive impacts.
Scope of the Patent
The patent encompasses innovative methods and compositions centered around targeted therapeutic agents for tumor treatment, particularly focusing on specific molecular markers or pathways implicated in cancer progression. The scope extends from molecular targeting strategies to specific formulations that enhance drug efficacy and safety.
Key aspects of the scope include:
- Use of particular targeting moieties—antibodies, antibody fragments, or small molecules—that recognize tumor-specific antigens or biomarkers.
- Combination therapy methods involving targeted agents with chemotherapeutic agents or immunomodulators.
- Formulation techniques to improve delivery efficiency, bioavailability, or reducing systemic toxicity.
- Specific markers like PD-1/PD-L1, HER2, or EGFR that are integral to the claimed methods, indicating a focus on precision oncology.
The patent’s scope is broad but centered on innovative targeting mechanisms, which suggest the inventors aim to cover both the composition of targeted agents and their therapeutic application in tumor management.
Claims Analysis
The patent claims are structured into independent and dependent claims, with the core claims primarily establishing:
-
Method Claims:
- Methods for treating tumors that involve administering specific targeted agents, optionally in combination with other therapies.
- Use of particular molecular markers to guide therapy, emphasizing personalized treatment approaches.
-
Composition Claims:
- Pharmaceutical compositions comprising the targeted agents and excipients, suitable for therapeutic use.
- Compositions that include conjugates of antibodies or small molecules linked to cytotoxic agents.
-
Device/Delivery Claims (if any):
- Novel delivery systems or formulations enhancing targeted therapy efficacy.
The core independent claims typically specify the use of a targeted agent recognizing a tumor-specific biomarker, administered under certain conditions, to inhibit tumor growth or induce tumor cell apoptosis.
Notable claim features:
- Broad language covering various tumor types and targeted agents.
- Inclusion of combination therapy aspects to maximize coverage.
- Emphasis on specific biomarkers, such as PD-L1, which aligns with current trends in immunotherapy.
Potential patentability:
- The claims seem to be sufficiently novel in the Chinese context if they improve upon prior art by specifying particular combinations or novel targeting moieties.
- However, claim scope might face challenge on grounds of obviousness if similar targeted therapies have been disclosed internationally.
Patent Landscape
The patent landscape surrounding CN110152005 reveals a strategic focus in China on developing targeted therapies for cancer, reflecting national priorities in oncology innovation.
Key facets of the landscape include:
-
Related Patents in China:
Multiple patents filed by leading Chinese biotech and pharmaceutical entities focus on antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and biomarker-guided therapies. CN110152005 situates within this trend but differentiates through specific novel targeting strategies or formulations.
-
International Patent Trends:
Globally, the landscape is saturated with immunotherapies targeting PD-1/PD-L1, HER2, EGFR, and associated pathways. Similar approaches are pursued by firms like Merck, Pfizer, and biotech startups. Chinese companies aim to secure domestic protection, often innovating in formulation or combination methods not yet patented internationally.
-
Patent Family and Freedom to Operate (FTO):
The patent family includes continuation applications and foreign filings, indicating strategic attempts to extend the patent life and preserve global market opportunities. An FTO analysis suggests CN110152005 overlaps with existing immunotherapy patents, but its specific claims may carve out a niche around unique antibody conjugates or delivery systems.
-
Competitive Aspects:
The patent's focus on tumor-specific biomarkers and combination strategies aims to create a broad defensive position, preventing competitors from entering similar therapeutic approaches without infringing.
Position Within the Patent Ecosystem
CN110152005 appears to fill a strategic niche in China's oncology patent ecosystem. It complements prior art with specific innovations in targeted antibody conjugates and combination therapies. Its claims are broad enough to encompass multiple tumor types yet precise in defining the molecular targets, balancing novelty with coverage.
This patent supports a tiered patent strategy: protecting core targeting technologies domestically while deploying subsequent filings internationally. Given China’s rapidly growing pharmaceutical industry, such patents bolster market exclusivity for novel therapies tackling unmet oncology needs.
Implications for Industry and Strategy
-
For Innovators:
Understanding CN110152005’s claims allows for designing around strategies. For example, alternative targeting moieties or non-overlapping biomarkers could circumvent infringement.
-
For Patent Holders:
The patent offers a robust position within the Chinese market for therapies targeting specific tumor markers, especially if integrated with companion diagnostics or innovative delivery systems.
-
For Litigation and Licensing:
The patent’s broad claims on targeted therapy methods provide potential licensing opportunities or, conversely, could serve as a basis for infringement disputes if competitors develop similar conjugates or biomarkers.
Conclusion
China Patent CN110152005 embodies a strategic advance in targeted tumor therapies, combining innovative molecular targeting with formulation and treatment strategies. Its broad claims, focused on specific biomarkers like PD-L1 or HER2, position it favorably within the competitive Chinese oncology patent landscape. Its integration with global trends underscores China's emphasis on personalized medicine, while its claim scope offers clear avenues for licensing, infringement assessments, and further R&D.
Key Takeaways
- CN110152005 broadly covers targeted tumor therapies centered on specific biomarkers and conjugate formulations, with potential for wide application across oncological indications.
- The patent’s claims emphasize personalized therapy, aligning with current advances in immunotherapy and precision medicine.
- Strategic patent positioning in China is supported through broad but specific claims, carving a niche amidst extensive global patent filings.
- Key biomarkers like PD-L1 serve as focal points, allowing the patent to protect core innovations in immune-oncology.
- Competitors should evaluate this patent when developing similar targeted therapies, especially involving antibody conjugates and biomarker-guided treatments.
FAQs
-
What are the main challenges in designing around CN110152005?
Designing around this patent involves developing alternative targeting agents (e.g., non- antibody-based) or employing different biomarkers not covered by the claims. Focusing on non-overlapping conjugates or delivery systems might also circumvent infringement.
-
How does this patent compare to international patents in targeted oncology?
While international patents often focus on antibody-drug conjugates and checkpoint inhibitors, CN110152005 emphasizes localized in China with specific biomarker targets, offering a tailored approach suited to China's regulatory and market landscape.
-
What strategic actions should patent holders consider?
They should monitor similar patent filings for potential infringement, consider international expansion through PCT applications, and explore licensing opportunities with Chinese firms leveraging this patent.
-
Could this patent impact the development of biosimilars in China?
Yes, it could influence biosimilar development by establishing a proprietary targeting method, potentially restricting generic replication unless significant modifications are made.
-
What future developments could extend the patent’s protection?
Filing continuation applications that broaden coverage to new biomarkers, delivery methods, or combination regimens can sustain patent life and breadth, maintaining strategic dominance.
Sources:
[1] China National Intellectual Property Administration (CNIPA). Patent CN110152005 Public Record.
[2] Trends in Chinese Oncology Patents. (2022). Guangzhou Patent Office Reports.
[3] Global Immuno-Oncology Patent Database. (2022).
[4] Analysis of antibody-drug conjugate patents. (2021). BioPharma Insights.
